The global patient-derived xenograft model market size is expected to register a significant CAGR of over 13% during the forecast period from 2022 to 2028. The increasing rate of cancer prevalence and the growing research & development activities in the pharmaceutical industry are some major factors driving the market growth. Furthermore, the rising demand for personalized medicine and the increasing awareness program regarding cancer by the government is further anticipated to propel the market growth. Moreover, the increasing demand for humanized PDX model is anticipated to drive the growth opportunity in the global market.
Market Drivers:
Increasing Demand for Personalized Medicine: Personalized medicine aims to tailor treatment approaches based on an individual patient’s characteristics, including their unique tumor biology. PDX models provide a valuable tool for studying tumor behavior and drug responses in a patient-specific manner. The increasing demand for personalized medicine drives the adoption of PDX models for preclinical research and drug development.
Enhanced Predictability and Translatability: PDX models offer a high degree of predictability and translatability, allowing researchers to better understand how a patient’s tumor may respond to different treatment options. The ability of PDX models to retain the key biological characteristics and heterogeneity of patient tumors enhances their relevance and utility in preclinical drug testing and biomarker discovery.
Advancements in Tumor Biology Research: The field of tumor biology research is continuously advancing, with a focus on unraveling the complex mechanisms of cancer growth, metastasis, and drug resistance. PDX models provide researchers with a powerful tool to investigate these aspects of tumor biology in a more clinically relevant context. The demand for PDX models is driven by the need to gain deeper insights into tumor biology and identify potential therapeutic targets.
Rise in Oncology Research and Drug Development: The increasing prevalence of cancer and the urgent need for effective cancer treatments have led to a surge in oncology research and drug development activities. PDX models serve as valuable preclinical models for evaluating the efficacy and toxicity of potential cancer therapeutics. The growing focus on oncology research and drug development fuels the demand for PDX models.
Collaboration and Partnerships: Collaborations and partnerships between academic institutions, pharmaceutical companies, and contract research organizations (CROs) contribute to the growth of the PDX model market. These collaborations facilitate the sharing of resources, expertise, and access to a diverse range of patient-derived tumor samples. Such partnerships accelerate the development and adoption of PDX models in preclinical research and drug discovery.
Increasing Availability of Patient Tumor Samples: The availability of high-quality patient tumor samples is crucial for establishing PDX models. Advances in tissue collection, preservation, and banking technologies have made it easier to obtain and store patient tumor samples for PDX model development. The growing availability of patient tumor samples supports the expansion of the PDX model market.
Regulatory Support and Guidelines: Regulatory agencies have recognized the value of PDX models in preclinical drug testing and translational research. Regulatory support and guidelines that highlight the importance of incorporating PDX models in drug development strategies drive their adoption in the pharmaceutical industry. This support enhances the market growth of PDX models.
Potential for Reduced Animal Testing: PDX models have the potential to reduce the reliance on traditional animal testing models in preclinical research. By utilizing patient-derived tumor tissue, PDX models provide a more clinically relevant alternative that better recapitulates human tumor behavior. The potential for reduced animal testing aligns with ethical considerations and drives the demand for PDX models.
Growing Focus on Precision Oncology: Precision oncology aims to match cancer treatments to individual patients based on the specific molecular characteristics of their tumors. PDX models enable researchers to evaluate the response of patient tumors to different treatment strategies, facilitating the identification of effective targeted therapies. The growing focus on precision oncology drives the demand for PDX models.
Advancements in Model Development and Characterization: Ongoing advancements in PDX model development and characterization techniques contribute to their wider adoption in preclinical research. Improved engraftment rates, faster model generation, and the ability to preserve tumor heterogeneity are among the key advancements that enhance the utility of PDX models.
Market Snapshot:
| Benchmark Year | 2022 | ||
| Market Size | lock | ||
| Market Growth (CAGR) | > 13% (2023-2030) | ||
| Largest Market Share | North America | ||
| Analysis Period | 2020-2030 | ||
| Market Players | Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, and Envigo |
Market Insights:
The global patient-derived xenograft model market is bifurcated into tumor type, model type, end-user, and geography. On the basis of tumor type, the market is further segmented into lung cancer, pancreatic cancer, prostate cancer, breast cancer, and others. The breast cancer segment dominated the global market in 2021 and accounted to hold the largest revenue share of around 1/3 market share by the end of the analysis period. The higher prevalence of breast cancer among women across the globe is a major factor to drive the segment growth. On the flip side, the other cancers segment is accounted to register the fastest growth rate over the forecast period. The segment includes colorectal, ovarian, sarcoma, renal cell carcinoma, and other cancers.
On the basis of model type, the market is segmented into mice and rat models. The mice model segment dominated the global patient-derived xenograft model market in 2021 and is anticipated to hold the largest revenue share of over 2/3 market share by the end of the analysis period. Factors such as ease of procurement, ease of manipulation, and minimum facility requirement for keeping the mice model under observation as compared to rats are driving the segment growth.
To know more about the research report, request sample papers
The patient-derived xenograft model comprehensive study analyzes industry trends, market size, competitive analysis, and market forecast – 2022 to 2028. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.
The patient-derived xenograft model market research report presents the analysis of each segment from 2019 to 2028 considering 2020 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2021 to 2027.
Historical & Forecast Period
- 2019-20 – Historical Year
- 2021 – Base Year
- 2022-2028 – Forecast Period
Market Segmentation:
By Tumor Type:
- Lung Cancer
- Pancreatic Cancer
- Prostate Cancer
- Breast Cancer
- Others
By Model Type:
- Mice
- Rats
By End-User:
- Pharmaceutical And Biopharmaceutical Companies
- Academic & Research Institutes
- CROs & CDMOs
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Regional Analysis:
Geographically, North America dominated the global patient-derived xenograft model market in 2021 and is expected to maintain its dominance over the forecast period. The region is accounted to hold a significant market share around half of the market in 2021. The increasing rate of cancer prevalence, growing investment by the government and private sector, and the presence of some major players are some major factors driving the market growth in the region. Furthermore, the rising awareness and increasing R&D activities are further expected to fuel market growth in North America.
Competitive Assessment:
Some of the major market players operating in the global patient-derived xenograft model market are Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, and Envigo. Companies are exploring markets through expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.
Key Companies:
- Charles River Laboratories
- The Jackson Laboratory
- Crown Bioscience
- Altogen Labs
- Envigo
- WuXi AppTec
- Oncodesign
- Hera Biolabs
- XenTech
- Abnova Corp.
Key Questions Answered by Patient-derived Xenograft Model Market Report
- Global patient-derived xenograft model market forecasts from 2022-2028
- Regional market forecasts from 2022-2028 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
- Country-level forecasts from 2022-2028 covering 15 major countries from the regions as mentioned above
- Patient-derived xenograft model submarket forecasts from 2022-2028 covering the market by tumor type, by model type, by end-user, and geography
- Various industry models such as SWOT analysis, Value Chain Analysis about the market
- Analysis of the key factors driving and restraining the growth of the global, regional, and country-level patient-derived xenograft model markets from 2022-2028
- Competitive Landscape and market positioning of top 10 players operating in the market
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.4. Assumptions
2. Executive Summary
2.1. Global Patient-derived Xenograft Model Market Portraiture
2.2. Global Patient-derived Xenograft Model Market, by Tumor Type, 2021 (USD Mn)
2.3. Global Patient-derived Xenograft Model Market, by Model Type, 2021 (USD Mn)
2.4. Global Patient-derived Xenograft Model Market, by End-User, 2021 (USD Mn)
2.5. Global Patient-derived Xenograft Model Market, by Geography, 2021 (USD Mn)
3. Global Patient-derived Xenograft Model Market Analysis
3.1. Patient-derived Xenograft Model Market Overview
3.2. Market Inclination Insights
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Challenges
3.3.3. Opportunities
3.4. Attractive Investment Proposition
3.5. Competitive Analysis
3.6. Porter’s Five Force Analysis
3.6.1. Bargaining Power of Suppliers
3.6.2. Bargaining Power of Buyers
3.6.3. Threat of New Entrants
3.6.4. Threat of Substitutes
3.6.5. Degree of Competition
3.7. COVID-19 Impact Analysis
4. Global Patient-derived Xenograft Model Market By Tumor Type, 2019 – 2028 (USD Mn)
4.1. Overview
4.2. Lung Cancer
4.3. Pancreatic Cancer
4.4. Prostate Cancer
4.5. Breast Cancer
4.6. Others
5. Global Patient-derived Xenograft Model Market By Model Type, 2019 – 2028 (USD Mn)
5.1. Overview
5.2. Mice
5.3. Rats
6. Global Patient-derived Xenograft Model Market By End-User, 2019 – 2028 (USD Mn)
6.1. Overview
6.2. Pharmaceutical And Biopharmaceutical Companies
6.3. Academic & Research Institutes
6.4. CROs & CDMOs
7. North America Patient-derived Xenograft Model Market Analysis and Forecast, 2019 – 2028 (USD Mn)
7.1. Overview
7.2. North America Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
7.3. North America Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
7.4. North America Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
7.5. North America Patient-derived Xenograft Model Market by Country, (2019-2028 USD Mn)
7.5.1. U.S.
7.5.1.1. U.S. Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
7.5.1.2. U.S. Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
7.5.1.3. U.S. Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
7.5.2. Canada
7.5.2.1. Canada Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
7.5.2.2. Canada Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
7.5.2.3. Canada Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
8. Europe Patient-derived Xenograft Model Market Analysis and Forecast, 2019 – 2028 (USD Mn)
8.1. Overview
8.2. Europe Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
8.3. Europe Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
8.4. Europe Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
8.5. Europe Patient-derived Xenograft Model Market by Country, (2019-2028 USD Mn)
8.5.1. Germany
8.5.1.1. Germany Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
8.5.1.2. Germany Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
8.5.1.3. Germany Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
8.5.2. U.K.
8.5.2.1. U.K. Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
8.5.2.2. U.K. Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
8.5.2.3. U.K. Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
8.5.3. France
8.5.3.1. France Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
8.5.3.2. France Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
8.5.3.3. France Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
8.5.4. Italy
8.5.4.1. Italy Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
8.5.4.2. Italy Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
8.5.4.3. Italy Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
8.5.5. Rest of Europe
8.5.5.1. Rest of Europe Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
8.5.5.2. Rest of Europe Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
8.5.5.3. Rest of Europe Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
9. Asia Pacific Patient-derived Xenograft Model Market Analysis and Forecast, 2019 – 2028 (USD Mn)
9.1. Overview
9.2. Asia Pacific Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
9.3. Asia Pacific Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
9.4. Asia Pacific Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
9.5. Asia Pacific Patient-derived Xenograft Model Market by Country, (2019-2028 USD Mn)
9.5.1. China
9.5.1.1. China Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
9.5.1.2. China Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
9.5.1.3. China Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
9.5.2. Japan
9.5.2.1. Japan Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
9.5.2.2. Japan Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
9.5.2.3. Japan Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
9.5.3. India
9.5.3.1. India Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
9.5.3.2. India Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
9.5.3.3. India Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
9.5.4. Rest of Asia Pacific
9.5.4.1. Rest of Asia Pacific Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
9.5.4.2. Rest of Asia Pacific Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
9.5.4.3. Rest of Asia Pacific Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
10. Latin America (LATAM) Patient-derived Xenograft Model Market Analysis and Forecast, 2019 – 2028 (USD Mn)
10.1. Overview
10.2. Latin America Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
10.3. Latin America Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
10.4. Latin America Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
10.5. Latin America Patient-derived Xenograft Model Market by Country, (2019-2028 USD Mn)
10.5.1. Brazil
10.5.1.1. Brazil Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
10.5.1.2. Brazil Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
10.5.1.3. Brazil Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
10.5.2. Mexico
10.5.2.1. Mexico Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
10.5.2.2. Mexico Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
10.5.2.3. Mexico Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
10.5.3. Rest of Latin America
10.5.3.1. Rest of Latin America Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
10.5.3.2. Rest of Latin America Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
10.5.3.3. Rest of Latin America Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
11. Middle East and Africa Patient-derived Xenograft Model Market Analysis and Forecast, 2019 – 2028 (USD Mn)
11.1. Overview
11.2. MEA Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
11.3. MEA Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
11.4. MEA Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
11.5. Middle East and Africa Patient-derived Xenograft Model Market, by Country, (2019-2028 USD Mn)
11.5.1. GCC
11.5.1.1. GCC Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
11.5.1.2. GCC Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
11.5.1.3. GCC Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
11.5.2. South Africa
11.5.2.1. South Africa Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
11.5.2.2. South Africa Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
11.5.2.3. South Africa Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
11.5.3. Rest of MEA
11.5.3.1. Rest of MEA Patient-derived Xenograft Model Market by Tumor Type, (2019-2028 USD Mn)
11.5.3.2. Rest of MEA Patient-derived Xenograft Model Market by Model Type, (2019-2028 USD Mn)
11.5.3.3. Rest of MEA Patient-derived Xenograft Model Market by End-User, (2019-2028 USD Mn)
12. Company Profiles
12.1. Charles River Laboratories
12.1.1. Business Description
12.1.2. Financial Health and Budget Allocation
12.1.3. Product Positions/Portfolio
12.1.4. Recent Development
12.1.5. SWOT Analysis
12.2. The Jackson Laboratory
12.2.1. Business Description
12.2.2. Financial Health and Budget Allocation
12.2.3. Product Positions/Portfolio
12.2.4. Recent Development
12.2.5. SWOT Analysis
12.3. Crown Bioscience
12.3.1. Business Description
12.3.2. Financial Health and Budget Allocation
12.3.3. Product Positions/Portfolio
12.3.4. Recent Development
12.3.5. SWOT Analysis
12.4. Altogen Labs
12.4.1. Business Description
12.4.2. Financial Health and Budget Allocation
12.4.3. Product Positions/Portfolio
12.4.4. Recent Development
12.4.5. SWOT Analysis
12.5. Envigo
12.5.1. Business Description
12.5.2. Financial Health and Budget Allocation
12.5.3. Product Positions/Portfolio
12.5.4. Recent Development
12.5.5. SWOT Analysis
12.6. WuXi AppTec
12.6.1. Business Description
12.6.2. Financial Health and Budget Allocation
12.6.3. Product Positions/Portfolio
12.6.4. Recent Development
12.6.5. SWOT Analysis
12.7. Oncodesign
12.7.1. Business Description
12.7.2. Financial Health and Budget Allocation
12.7.3. Product Positions/Portfolio
12.7.4. Recent Development
12.7.5. SWOT Analysis
12.8. Hera Biolabs
12.8.1. Business Description
12.8.2. Financial Health and Budget Allocation
12.8.3. Product Positions/Portfolio
12.8.4. Recent Development
12.8.5. SWOT Analysis
12.9. XenTech
12.9.1. Business Description
12.9.2. Financial Health and Budget Allocation
12.9.3. Product Positions/Portfolio
12.9.4. Recent Development
12.9.5. SWOT Analysis
12.10. Abnova Corp.
12.10.1. Business Description
12.10.2. Financial Health and Budget Allocation
12.10.3. Product Positions/Portfolio
12.10.4. Recent Development
12.10.5. SWOT Analysis
$ 5200/- Multi User License
We understand that every business has unique requirements. This report can be customized based on:
- Deep regional & country-level market intelligence
- Application-specific and end-use industry segmentation
- Competitive landscape & strategic benchmarking
- Go-to-market and expansion strategy insights
- Custom data cuts aligned to your business goals
- Structured Primary Research Framework
- On-Demand Industry Expert Interviews Available
- Dedicated Analyst Support
- Custom Data On Request
- Post-Purchase Strategy Consultation
- Complimentary 30-min Analyst Session
- 30% of Our Clients Are Returning Enterprise Buyers
Our Clients
